top of page

Biopharma Daily Stock Updates - 11/03/21

$XBI $134.15 +2.2%

 

Covid Updates

$SRNE +4.0% Sorrento Receives Brazilian Health Regulatory Agency (ANVISA) Approval for COVISTIX™ (COVID-19 Virus Antigen Detection Test) for Brazil. source


$OCGN -18.8% Ocugen Statement Regarding WHO Emergency Use Listing Announcement.


$INO +1.4% INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India. source



Pipeline Updates

$ALEC +4.4% Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference and SITC Annual Meeting source


$OYST +2.4% Oyster Point Pharma’s TYRVAYA™ (varenicline solution) Nasal Spray is Now Available at U.S. Regional Wholesalers for Distribution to Pharmacies for the Treatment of the Signs and Symptoms of Dry Eye Disease source


$CDXS +0.3% Codexis and Nestlé Health Science Initiate a Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency source


$XNCR +5.2% Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium. source


$RFL +5.2% European Medicines Agency Grants Orphan Drug Designation to Rafael Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Relapsed or Refractory Burkitt's Lymphoma. source


$NERV -3.4% Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission. source


$PHAS -5.7% PhaseBio Announces Topline Results From Phase 2b Trial for Bentracimab. source


$CMPS +1.1% COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder. source


$BBIO -2.0% BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease. source


$ONCY -0.9% Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers. source


$ALKS +3.1% Alkermes to Present Data on Nemvaleukin Alfa at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting. source


$AVRO +7.5% AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome. source


$PSTV +1.1% Plus Therapeutics to Host Key Opinion Leader Roundtable on ReSPECT™-GBM Trial. source


$CALT +6.0% Calliditas announces poster presentations at ASN Digital Kidney Week 2021. source


$PSNL -0.3% Personalis Announces Updates to NeXT Platform™ Incorporating Additional Key Profiling Capabilities for Advancing Oncology Biomarkers. source


$GNFT +3.3% New Clinical Data on GENFIT’s Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting®. source

 

Posted by FS/JM

0 comments
bottom of page